Special Programme on Human Reproduction
The Human Reproduction Programme -UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) is a WHO co-sponsored research programme on human reproduction. HRP is based at the WHO headquarters in Geneva, Switzerland. Its goal is to support and coordinate research on a global scale. It is part of the Sexual and Reproductive Health and Research (SRH) department of the WHO.
It resulted in the following marketed combined injectable contraceptives:
- Estradiol cypionate/medroxyprogesterone acetate (EC/MPA; brand names Cyclofem, Lunelle; code names HRP-112, Cyclo-Provera)
- Estradiol valerate/norethisterone enanthate (EV/NETE; brand name Mesigyna; code name HRP-102)
And in the following never-marketed progestogen injectable contraceptives:
- Levonorgestrel butanoate (LNG-B; code name HRP-002)
- Levonorgestrel cyclobutylcarboxylate (code name HRP-001)
- Levonorgestrel cyclopropylcarboxylate (code name HRP-003)